Compare First Solar, Inc. (FSLR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Pfizer Inc — how do they compare? First Solar, Inc. trades at $178.23 (market cap $19.22B), while Pfizer Inc trades at $28.16 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 8.2× First Solar, Inc.'s market cap, and Pfizer Inc pays a 6.18% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 75 Days and Pfizer Inc for 158 Days on average.
| FSLR | PFE | |
|---|---|---|
Market Cap | $19.22B | $158.56B |
Volume | 2,067,793 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $318.30 | $29.02 |
52-Week Low | $172.11 | $23.67 |
Typical Hold Time | 75 Days | 158 Days |
Enterprise Value | $17.69B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $180.13, up 0.18% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 32.47% net income margin and trades at a P/E of 11.03, below industry averages. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Analyst consensus is a Moderate Buy with a $267.59 price target, signaling significant upside potential despite recent sector-wide pressures and high put option activity noted in early October 2026.
The outlook for FSLR is mixed: strong earnings growth and attractive valuation support long-term upside, but near-term risks include solar sector volatility, rising borrowing costs, and patent litigation. Investors face a divergence between bullish fundamentals and bearish technicals, with the stock trading 33% below analyst targets. Key catalysts are Q3 2026 earnings and resolution of legal challenges, while headwinds include interest rate sensitivity and competitive pressures.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
